New York City's life sciences real estate market is carrying the highest vacancy rate of any U.S. Market, raising questions about the long-term viability of the sector in the city, particularly in Harlem where several purpose-built lab buildings have sat empty since delivery.
The sector recorded a 37% availability rate at the end of the first quarter, according to JLL, far above any other market in the country. Asking rents of $99.17 per square foot make New York the most expensive market for lab space, yet leasing activity remains minimal, industry observers say.
Quick take
- NYC life sciences availability stood at 37% at the end of Q1, the highest of any U.S. Market, per JLL
- Asking rents average $99.17 per square foot, compared to Boston's $76.72
- A Harlem conversion project valued at $700 million faces foreclosure proceedings
- A 10-storey, 193,000 square foot Harlem lab building delivered in 2024 remains unleased
- Select clusters including Alexandria Real Estate Equities' portfolio and an Innolabs facility in Long Island City are performing well
What it means for you
The data presents a sharply bifurcated picture. Select clusters are functioning: Alexandria's NYC portfolio sits 95.5% occupied, with tenants including pharmaceutical names like Bristol Myers Squibb and Pfizer. Innolabs in Long Island City signed deals with NYU Langone totaling more than 150,000 square feet and recently added robotics company Rover for 16,000 square feet. These deals suggest that tenants with genuine scientific mandates and institutional backing are willing to pay New York's premium rents—if the location and building quality meet their standards.
Harlem tells a different story. Two large purpose-built lab buildings remain vacant, one facing foreclosure. The neighbourhood was positioned as an emerging life sciences hub following the pandemic, but the pipeline overshot demand by a wide margin. For investors who acquired or developed in this corridor expecting a near-term tenant base, the vacancy carries real financial consequences.
Why this matters
Life sciences real estate is not a monolithic category. The sector requires specific infrastructure—floor loads, ventilation, power redundancy, chemical waste systems—that general office cannot easily replicate. Buildings purpose-built for biotech or pharmaceutical use command premiums when occupied but sit in a difficult limbo when demand does not materialise.
The vacancy rate also reflects the concentration of deal-making in established hub markets. Industry observers note that leasing growth is expected to remain focused on San Francisco, San Diego, and Boston before filtering to secondary markets like New York. That trajectory suggests patience is required before Harlem's lab inventory finds its tenant base.
Federal research funding adds another variable. NIH grants dropped from $44.9 billion in fiscal year 2024 to $35.3 billion in fiscal year 2025, with disruptions affecting more than one in five grants nationally during the second Trump administration. New York has seen most grants restored, though $2.1 billion of the $4 billion allocated for state projects hasn't yet been distributed.
For commercial real estate investors, the Harlem experience is a cautionary tale about supply-driven positioning in sectors where demand remains uncertain. The premium rents achievable in New York are real, but they only translate to value if occupancy follows.
A worked example
Say you are evaluating a commercial real estate fund considering exposure to emerging life sciences markets. A 37% vacancy rate in New York versus stronger leasing in established markets changes the risk calculus significantly. A fund targeting diversification into secondary life sciences hubs would need to account for extended lease-up periods and potential reconfiguration costs if purpose-built lab space needs to pivot to general commercial or healthcare use. The Harlem buildings illustrate how quickly a thesis can be tested by market reality.
What to watch next
Track whether leasing activity picks up in NYC's established life sciences corridors before Harlem sees absorption. Also watch whether the vacant Harlem buildings are sold or repositioned, which could offer an entry point for investors with a longer time horizon.
Bottom line: NYC life sciences real estate has a serious vacancy problem, but the market is not uniformly weak. Established clusters with institutional tenants are performing. Harlem represents overbuilding that the market will eventually absorb—but not quickly.
Frequently asked questions
What is the current vacancy rate for life sciences real estate in New York City?
Availability stood at 37% at the end of the first quarter, according to JLL, the highest rate of any U.S. Market.
How do NYC lab rents compare to other markets?
Asking rents average $99.17 per square foot in New York, compared to $76.72 in Boston, the largest life sciences market in the country.
What is happening with the Taystee Lab Building in Harlem?
The $700 million conversion by Janus Property Co. Has been empty since opening in 2022 and is now facing a foreclosure suit.
Are all NYC life sciences clusters struggling?
No. Alexandria Real Estate Equities' portfolio is 95.5% occupied, and Innolabs in Long Island City is fully leased, indicating that well-located, institutional-grade lab space can perform in the NYC market.
Where is life sciences leasing growth expected to focus?
Industry observers indicate growth will remain concentrated in established hub markets like San Francisco, San Diego, and Boston before extending to secondary markets including New York.